Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Clinical Study Evaluating the Safety and Preliminary Efficacy of Universal Allogeneic CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Refractory Primary Immune Thrombocytopenia

NCT07416032 is registered in ClinicalTrials.gov with Union Hospital, Tongji Medical College, Huazhong University of Science and Technology as lead sponsor.

NCT NCT07416032
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07416032 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Clinical Study Evaluating the Safety and Preliminary Efficacy of Universal Allogeneic CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Refractory Primary Immune Thrombocytopenia
Lead sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase
Phase 1
Overall status
Not yet recruiting
Start date
February 20, 2026
Completion date
March 1, 2029
Enrollment
27 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

immune thrombocytopenia (itp)